| Schedule of Reconciliation Consolidated Net Loss |
The
following table presents certain financial data for the Company’s two reportable segments and a reconciliation to the
Company’s consolidated net loss.
Schedule
of Reconciliation Consolidated Net Loss
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
Pharmaceuticals
|
|
|
Computing Technology |
|
| |
|
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
| Sales |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
| Product Cost of Sales |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
| Gross Income |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Operating Expenses |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Administrative Expenses |
|
|
2,013,710 |
|
|
|
4,161,907 |
|
|
|
1,722,816 |
|
|
|
- |
|
| Research and Development Expenses |
|
|
3,045,977 |
|
|
|
3,441,010 |
|
|
|
425,864 |
|
|
|
- |
|
| Stock-Based Compensation |
|
|
1,937,691 |
|
|
|
- |
|
|
|
236,833 |
|
|
|
|
|
| Franchise Tax Expense |
|
|
150,038 |
|
|
|
- |
|
|
|
50,013 |
|
|
|
- |
|
| Warrant Issuance Expense |
|
|
- |
|
|
|
- |
|
|
|
264,417 |
|
|
|
- |
|
| Segment Net Loss |
|
|
(7,147,415 |
) |
|
|
(7,602,917 |
) |
|
|
(2,699,942 |
) |
|
|
- |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Reconcilement of Net Loss |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Adjustments and Reconciling Items |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Stock Based Compensation |
|
|
1,325,144 |
|
|
|
1,057,271 |
|
|
|
- |
|
|
|
- |
|
| Series F Warrant Issuance Expenses |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
| Series F-1 Warrant Issuance Expenses |
|
|
- |
|
|
|
539,097 |
|
|
|
- |
|
|
|
- |
|
| Series G Warrant Issuance Expenses |
|
|
- |
|
|
|
969,505 |
|
|
|
- |
|
|
|
- |
|
| Series H Warrant Issuance Expenses |
|
|
- |
|
|
|
- |
|
|
|
264,417 |
|
|
|
- |
|
| Dividends Paid on Series H Preferred Stock |
|
|
- |
|
|
|
- |
|
|
|
99,437 |
|
|
|
- |
|
| Interest and Dividend Income |
|
|
156,042 |
|
|
|
351,809 |
|
|
|
69,346 |
|
|
|
- |
|
| Gains on Sales of Marketable Securities |
|
|
2,176 |
|
|
|
976 |
|
|
|
- |
|
|
|
- |
|
| Unrealized Gains on Marketable Securities |
|
|
(1,435 |
) |
|
|
671 |
|
|
|
40,106 |
|
|
|
- |
|
| Change in Fair Value of Derivative Liabilities |
|
|
1,303,000 |
|
|
|
(388,000 |
) |
|
|
(320,000 |
) |
|
|
- |
|
| Change in Fair Value of Warrant Liabilities |
|
|
- |
|
|
|
(4,410,000 |
) |
|
|
- |
|
|
|
- |
|
| Loss on Issuance of Series F-1 Convertible Preferred Stock |
|
|
- |
|
|
|
(3,737,000 |
) |
|
|
- |
|
|
|
- |
|
| Loss on Issuance of Series G Convertible Preferred Stock |
|
|
- |
|
|
|
(5,109,000 |
) |
|
|
- |
|
|
|
- |
|
| Loss on Impairment of Intangible |
|
|
(1,500,000 |
) |
|
|
- |
|
|
|
- |
|
|
|
- |
|
| Loss on FMV of Contingent Compensation |
|
|
- |
|
|
|
- |
|
|
|
(1,529,000 |
) |
|
|
- |
|
| Casualty Gain/(Loss) |
|
|
- |
|
|
|
100,000 |
|
|
|
- |
|
|
|
- |
|
| Total Adjustments and Reconciling Items |
|
|
(1,365,331 |
) |
|
|
(15,756,417 |
) |
|
|
(2,103,402 |
) |
|
|
- |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Consolidated Net Loss |
|
$ |
(5,782,084 |
) |
|
$ |
(23,359,334 |
) |
|
|
(596,540 |
) |
|
|
- |
|
|